Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy
| Autor: | Ruchira M. Jha, Stefania Mondello, Helen M. Bramlett, C. Edward Dixon, Deborah A. Shear, W. Dalton Dietrich, Kevin K.W. Wang, Zhihui Yang, Ronald L. Hayes, Samuel M. Poloyac, Philip E. Empey, Audrey D. Lafrenaye, Hong Q. Yan, Shaun W. Carlson, John T. Povlishock, Janice S. Gilsdorf, Patrick M. Kochanek |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Blood Glucose
Male 0301 basic medicine animal structures consortium cerebral edema controlled cortical impact contusion fluid percussion injury glyburide penetrating ballistic-like brain injury rat sulfonylurea receptor-1 Rats Sprague-Dawley 03 medical and health sciences 0302 clinical medicine Brain Injuries Traumatic Animals Hypoglycemic Agents Maze Learning Original Articles Rats Treatment Outcome 030104 developmental biology Neurology (clinical) 030217 neurology & neurosurgery |
| Zdroj: | J Neurotrauma |
| Popis: | Glibenclamide (GLY) is the sixth drug tested by the Operation Brain Trauma Therapy (OBTT) consortium based on substantial pre-clinical evidence of benefit in traumatic brain injury (TBI). Adult Sprague-Dawley rats underwent fluid percussion injury (FPI; n = 45), controlled cortical impact (CCI; n = 30), or penetrating ballistic-like brain injury (PBBI; n = 36). Efficacy of GLY treatment (10-μg/kg intraperitoneal loading dose at 10 min post-injury, followed by a continuous 7-day subcutaneous infusion [0.2 μg/h]) on motor, cognitive, neuropathological, and biomarker outcomes was assessed across models. GLY improved motor outcome versus vehicle in FPI (cylinder task, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|